A Phase 2 interventional study of lorigerlimab and docetaxel in Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms and Prostate Cancer Recurrent, sponsored by MacroGenics. Completed at 61 sites in 10 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-22.
Sponsored by MacroGenics · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 17 open to participants now, 23 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.
Among the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is the 14th largest by enrollment of the 42 interventional ones that give a count, is one of 6 that started in 2023, is one of 9 in phase 2, and was the 33rd registered.
85 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 28 are open to participants now.
Browse Prostatic Neoplasms, Castration-Resistant studies →17 of the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18+ · Men only
Flare Therapeutics Inc. · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States
Ages 18–115 · Men only
Novartis Pharmaceuticals · Sites in United States
Ages 18–115 · Men only
T.O.A.D. Oncology SA · Sites in United States, Australia, Canada and 2 more countries
Ages 18+ · Men only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (88%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 20 · Phase 3 8 · Phase 4 2
First in 2014; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 82 across 62 interventional studies indexed under Prostatic Neoplasms, Castration-Resistant.
Median enrollment 91 across the 42 interventional studies, 1,908 across the 6 observational. Of the 23 that completed or were terminated, 11 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
41 of 50 have an industry lead sponsor. The 10 most frequent:
MacroGenics is the lead sponsor of 42 studies on the registry; 4 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 11 (65%) have results posted.
MacroGenics has 4 studies filed under Prostatic Neoplasms, Castration-Resistant — fewer than ten, so there is no comparison to draw.
8 of the studies in Prostatic Neoplasms, Castration-Resistant with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225946Phase 3Janssen Research & Development, LLCA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | 2027-11-19 |
| NCT07697989Novartis PharmaceuticalsPluvicto Real-world Investigation in Survival in Metastatic CRPC | 2027-01-31 |
| NCT07677254Novartis PharmaceuticalsA Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer | 2027-05-31 |
| NCT07677267Novartis PharmaceuticalsA Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan | 2027-05-31 |
| NCT05519449Janux TherapeuticsStudy of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | 2027-07 |
Add all 8 to your calendar (.ics) → With an account.
Among the 50 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic castration-resistant prostate cancer (MCRPC) who receive lorigerlimab in addition to the standard of care (SOC) of docetaxel and prednisone. About 150 participants with mCRPC will be enrolled. Participants will be randomized in a 2:1 ratio to receive lorigerlimab with docetaxel and prednisone (experimental arm) or docetaxel and prednisone alone (standard-of-care arm).
Lorigerlimab+docetaxel or docetaxel will be administered intravenously (IV) in clinic on Day 1 of each 3-week cycle. Prednisone will be administered orally twice daily. Lorigerlimab will be administered for up to 35 cycles. Docetaxel and prednisone will be administered up to 10 cycles until treatment discontinuation criteria are met. Participants will undergo regular testing for signs of disease progression using computed tomography (CT) scans, magnetic resonance imaging (MRI) and prostate-specific antigen (PSA) blood tests. Participants will be asked to complete questionnaires about their health and well-being. Routine examinations and blood tests will be performed and evaluated by the study doctor.
Participants who have disease progression standard-of-care arm have the option of continuing on the study to receive lorigerlimab monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Lorigerlimab 6 mg/kg IV (up to 2 years) and docetaxel 75 mg/m\^2 IV every 3 weeks (up to 7 months) and prednisone 5 mg orally twice daily (up to 7 months).
Biological: lorigerlimab · Drug: docetaxel · Drug: Prednisone
Docetaxel 75 mg/m\^2 IV every 3 weeks and prednisone 5 mg orally twice daily.(up to 7 months)
Drug: docetaxel · Drug: Prednisone
Lorigerlimab is a DART® molecule that binds PD-1 and CTLA-4
Also known as: MGD019
Docetaxel Injection is a cytotoxic anticancer drug approved to treat prostate cancer
Also known as: Taxotere®
A corticosteroid drug approved for use with docetaxel in the treatment of prostate cancer
Median radiographic progression free survival (rPFS) determined by investigator review.
The rPFS is defined as the time from the date of randomization to the date of first documented PD per Prostate Cancer Working Group 3 (PCWG3) criteria or death from any cause, whichever occurs first.
Time frame: Every 9 weeks for the first year, followed by every 12 weeks for up to 3 more years
Objective response rate (ORR) per PCWG3 criteria
ORR is defined as the number of participants who have a best overall response of confirmed complete response (CR) or partial response (PR) without prior confirmed bone progression
Time frame: Every 9 weeks for the first year, followed by every 12 weeks for up to 3 more years
Duration of response (DoR)
DoR is the time from the date of initial tumor response (CR or PR) to the date of first disease progression or death from any cause, whichever occurs first.
Time frame: Every 9 weeks for the first year, then every 12 weeks for up to 4 years
Time to response (TTR)
TTR is defined as the time from the start of treatment to the first objective response (CR or PR).
Time frame: Every 9 weeks for the first year, followed by every 12 weeks for up to 3 more years
PSA50 response rate
PSA50 response is defined as a ≥ 50% decline in PSA from baseline with confirmation at least 3 weeks after the first documented reduction in PSA of ≥ 50%.
Time frame: Every 3 weeks up to 2 years, followed by every 12 weeks for up to 2 more years
PSA90 response rate
PSA90 response is defined as a ≥ 90% decline in PSA from baseline with confirmation at least 3 weeks after the first documented reduction in PSA of ≥ 90%.
Time frame: Every 3 weeks up to 2 years, followed by every 12 weeks for up to 2 more years
Time to PSA progression
Time to PSA progression is defined as the time from the date of randomization to the first documented PSA progression.
Time frame: Every 9 weeks for the first year, followed by every 12 weeks for up to 2 more years
Duration of PSA response
Duration of PSA response is defined as the time from the date of first PSA response to the earliest date of PSA progression.
Time frame: Every 3 weeks up to 2 years, followed by every 23 weeks for up to 2 more years.
Overall survival (OS)
OS is defined as the time from the date of randomization to the date of death from any cause.
Time frame: Throughout the study up to 4 years
Time to First Symptomatic Skeletal Event (SSE)
Time to first SSE is defined as the time from the date of randomization to the first occurrence of SSE from any cause.
Time frame: Throughout the study up to 4 years
Time to pain progression using the BPI-sf questionnaire
Time to pain progression is defined as the time interval from randomization to the first date a participant experiences pain progression. Higher scores indicate more severe pain.
Time frame: Every 9 weeks for the first year, followed by every 12 weeks for up to 2 more years
Pain severity using the Brief Pain Index - short form (BPI-sf) questionnaire
The BPI-sf pain severity score consists of 4 items that assess pain at its worst, least, average, and current pain intensity. The pain severity score is the average of the 4 item scores. Higher scores indicate more severe pain.
Time frame: Every 3 weeks up to 2 years
Pain interference using the BPI-sf questionnaire
The BPI-sf pain interference score includes 7 items: general activity, mood, walking ability, normal work, relations with other people, sleep, and enjoyment of life. The pain interference score is the average of the 7 interference items. Higher scores indicate more interference from pain in daily life.
Time frame: Every 3 weeks up to 2 years
Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire
The FACT-P consists of 27 items from the Functional Assessment of Cancer Therapy-General (FACT-G) that measure physical, social/family, emotional, and functional well-being and 12 items that compose the Prostate Cancer Subscale (PCS). Higher scores indicate greater impact of prostate cancer on daily life.
Time frame: Every 3 weeks up to 2 years
Description of types of adverse events (AEs) between treatment groups.
Number of participants with adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation
Time frame: Throughout treatment up to 27 months
Lorigerlimab maximum concentration or concentration at the end of infusion (Cmax)
The highest measured concentration of lorigerlimab in the bloodstream.
Time frame: Every 21-day cycle throughout the study, for an average of 1 year.
Lorigerlimab area under the concentration time curve (AUC)
AUC is the total amount of lorigerlimab in bloodstream after drug administration
Time frame: Every 21-day cycle throughout the study, for an average of 1 year.
Trough drug concentration (Ctrough or Cmin)
Trough concentration is the concentration measured before a subsequent dose of lorigerlimab
Time frame: Every 21-day cycle throughout the study, for an average of 1 year.
Clearance (CL)
Drug clearance is the amount of drug removed from the bloodstream by the body per unit of time
Time frame: Every 21-day cycle throughout the study, for an average of 1 year.
Volume of distribution (Vz)
The volume of distribution is related to how much drug is distributed to body tissues, or remains in the bloodstream.
Time frame: Every 21-day cycle throughout the study, for an average of 1 year.
Terminal half-life
Terminal elimination half-life is the time it takes for the concentration of the drug in plasma or serum to be reduced by 50%
Time frame: Every 21-day cycle throughout the study, for an average of 1 year.
Number of participants who develop anti-drug antibodies
Time frame: Throughout the study, up to 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2023 to primary completion in Feb 2026, 28 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lorigerlimab
Prostatic Neoplasms, Castration-Resistant →